Peptides Topic Hub
What the evidence says — and the FDA reclassification that reshaped the market.
"Peptides for weight loss" covers two very different worlds: FDA-approved peptide drugs like semaglutide and tirzepatide, and the grey market of research peptides sold as "not for human consumption." The 2026 FDA reclassification reshaped both.
Related topic hubs
- Safety — Grey-market and safety risks
- GLP-1 Guide — Approved GLP-1 drugs vs research peptides
- Retatrutide — Retatrutide as a peptide drug
Approved vs research peptides
| Category | Examples | Evidence | Legal status (US) |
|---|---|---|---|
| FDA-approved peptide drugs | Semaglutide, tirzepatide, liraglutide | Phase 3 pivotal trials, FDA review | Prescription only, fully legal |
| Investigational peptide drugs | Retatrutide, CagriSema, survodutide | Phase 2/3 trials published | Clinical trials only |
| Compounded peptides | Pharmacy-compounded semaglutide/tirzepatide during shortages | Same active ingredient, unregulated finished product | Legal via 503A/B pharmacies, scope narrowed in 2026 |
| Research peptides | AOD-9604, MOTS-C, BPC-157, growth-hormone fragments | Limited or no human weight-loss trial data | Sold "not for human use" — illegal to sell for consumption |
What the 2026 FDA reclassification changed
In early 2026 the FDA reclassified a large set of peptides. Some moved from the compounding-allowed list to a restricted list. Read the full picture in Are Peptides Legal in 2026?
Risk tiers
| Tier | Source | Typical risks |
|---|---|---|
| Lowest risk | Licensed pharmacy, prescribed drug | Known side effects from trial data |
| Moderate risk | Compounding pharmacy (503A/B) with prescription | Active-ingredient purity generally OK; dosing errors from non-standard strengths |
| High risk | Online "research use only" seller with COA | Contamination, mislabeled dose, inconsistent purity between batches |
| Highest risk | Anonymous marketplace, no COA, no return address | Counterfeit or wrong compound, bacterial contamination, no legal recourse |
For the full comparison between research peptides and approved GLP-1 drugs, see Peptides vs GLP-1 Drugs. For grey-market specifics, see Grey Market Retatrutide.
All peptides articles
4 articles
Are Peptides Legal in 2026? The FDA Reclassification Explained
RFK announced 14 banned peptides returning to legal compounding. What it means, which peptides, and how it affects weight loss drugs.
Updated March 2026
Grey Market Retatrutide: Risks, Dangers, and What You Should Know
Grey market retatrutide is unregulated, untested, and potentially dangerous. Here's what the data shows and how to access it safely.
Updated February 2026
Peptides for Weight Loss vs GLP-1 Drugs: What the Evidence Says
GLP-1 drugs have Phase 3 trials and FDA approval. Research peptides have failed trials and animal data. The full evidence comparison.
Updated March 2026
Retatrutide vs AOD-9604: Triple Agonist vs Growth Hormone Fragment
Retatrutide produced 28.7% weight loss in Phase 3 trials. AOD-9604 failed its largest trial. Here's how they compare.
Updated March 2026